Feb 25, 2016 7:30am EST Rigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
Jan 28, 2016 7:30am EST Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)
Jan 07, 2016 7:30am EST Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
Oct 27, 2015 7:30am EDT Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results
Sep 09, 2015 8:30am EDT Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
Jul 28, 2015 7:30am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results
